首页> 外文期刊>Medical dosimetry: official journal of the American Association of Medical Dosimetrists >Feasibility of 5-mm vs 2.5-mm width multileaf collimator in noncoplanar volumetric modulated arc stereotactic radiotherapy for multiple brain metastases
【24h】

Feasibility of 5-mm vs 2.5-mm width multileaf collimator in noncoplanar volumetric modulated arc stereotactic radiotherapy for multiple brain metastases

机译:用于多脑转移的非平板容量调制弧立体定向放疗中5毫米VS 2.5mm宽度准直器的可行性

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to examine the feasibility of noncoplanar volumetric modulated arc stereotactic radiotherapy (VMAT-SRT) using a 5-mm multileaf collimator (MLC) for multiple brain metastases. We identified 34 multiple-target cases (3 to 19 targets in each case) with a total of 257 of targets and constructed noncoplanar VMAT-SRT plans using 5-mm and 2.5-mm MLCs with 4-arc. The prescribed dose was 36 Gy/6 fr. Plans were evaluated using the Paddick conformity indices (PCI), Paddick gradient index (PGI), and normal brain dose (NBD, equal to the mean brain dose minus gross tumor volume). There were no significant differences in PCI (median [range]: 5 mm, 0.88 [0.78 to 0.94]; 2.5 mm, 0.89 [0.78 to 0.94]; p = 0.691), PGI (median [range]: 5 mm, 3.96 [2.21 to 6.63]; 2.5 mm, 3.96 [2.24 to 6.45]; p = 0.358), or NBD (median [range]: 5 mm, 7.5 Gy [2.5 to 12.4]; 2.5 mm, 7.5 Gy [2.5 to 12.5]; p = 0.675). The performance of the 5-mm MLC was not inferior to the 2.5-mm MLC in applications of noncoplanar VMAT-SRT for multiple brain metastases with regards to dose conformity, gradient, and NBD. This study provides the necessary background for generalizing noncoplanar VMAT-SRT approaches in treating multiple brain lesions. (C) 2019 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.
机译:本研究的目的是研究使用5mm Multreaf准直器(MLC)进行多种脑转移的非平板容量调制弧立体定向放射疗法(VMAT-SRT)的可行性。我们识别34个多目标情况(每种情况下的3至19个目标),总共257个目标和使用5毫米和2.5毫米MLC的非电量VMAT-SRT计划,具有4弧。规定剂量为36 gy / 6 fr。使用帕迪克符合性指数(PCI),帕迪克梯度指数(PGI)和正常脑剂量(NBD等于平均脑剂量减去总肿瘤体积)来评估计划。 PCI没有显着差异(中位数]:5 mm,0.88 [0.78至0.94]; 2.5 mm,0.89 [0.78至0.94]; p = 0.691),PGI(中位[范围]:5 mm,3.96 [ 2.21至6.63]; 2.5毫米,3.96 [2.24至6.45]; p = 0.358),或NBD(中位[范围]:5 mm,7.5 gy [2.5至12.4]; 2.5 mm,7.5 gy [2.5至12.5]; p = 0.675)。对于剂量符合性,梯度和NBD,5mm MLC的性能不差不等于非脑VMAT-SRT的非脑转移的应用中的2.5mm MLC。本研究为概括非脑病变的概括不均匀性vmat-srt方法提供了必要的背景。 (c)2019年美国医学剂量分子协会。由elsevier Inc.保留所有权利发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号